Antibody-drug conjugates in urothelial cancer
Antibody-drug conjugates in urothelial cancer
Prof. Sandy Srinivas
Prof. Sandy Srinivas takes a look at antibody-drug conjugates (ADCs) in urothelial cancer.
Prof. Sandy Srinivas
Medical Oncologist
Stanford University Medical Center
United States (US)
| 
5 min
|
Jul 2020
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Prof. Sandy Srinivas takes a look at antibody-drug conjugates (ADCs) in urothelial cancer, in particular the first-in-class drug, Enfortumab Vedotin, and the pivotal trial resulting in registration together with promising data in combination with checkpoint inhibitors as well as another ADC, Sacituzumab Govitecan, which targets Trop-2. Prof. Srinivas also discusses the development of ADCs for other GU tumour types.
GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.
Other programmes of interest
28 min
Other programmes developed by Prof. Sandy Srinivas
Prof. Sandy Srinivas
Medical Oncologist
Stanford University Medical Center
United States (US)
